section name header

Information

Eptifibatide is a GP IIb/IIIa receptor blocker used to prevent platelet aggregation. It is often seen in combination with aspirin and heparin to provide a comprehensive platelet blockade. Primary indications for use are in unstable angina, in non–Q-wave MI, and in the prevention of ischemic complications postpercutaneous cardiac intervention.

Dosage in Management of Unstable Angina

Infuse

  • Initial dosage of 180 mcg/kg IV over 1 to 2 minutes.
  • Follow by 2 mcg/kg/min IV for up to 72 hours.

If percutaneous coronary intervention is performed during eptifibatide therapy, infusion should be continued for 18 to 24 hours after the procedure to a maximum total duration of 96 hours of therapy.

Dosage in Patients Undergoing Angioplasty (Not Presenting with Unstable Angina)

Infuse

  • Initial dosage of 180 mcg/kg IV over 1 to 2 minutes, immediately before procedure.
  • Follow by 2 mcg/kg/min IV.
  • Then, a second 180 mcg/kg IV injection 10 minutes after the first.

The infusion should be continued until hospital discharge or for up to 18 to 24 hours; a minimum of 12 hours is recommended.

Considerations

  • Does not require a dedicated line because the drug is compatible with alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, morphine, NTG, and verapamil. It may be infused in the same line as 0.9 NS or D5NS. The only incompatibility is with Lasix.
  • Minimize arterial and venous punctures and intramuscular injections to minimize blood loss.
  • Properly care for femoral access site to minimize bleeding. Document a PTT of <45 seconds, and stop heparin 3 to 4 hours before pulling sheath.